CSF chromogranin A-like immunoreactivity in schizophrenia: Assessment of clinical and biochemical relationships

Abstract

Chromogranin A (CgA) is co-released with catecholamines and peptides and has a wide distribution in the brain. Chromogranin A provides a measure of tonic arousal. CSF CgA-like immunoreactivity (CgA-LI) was studied in 42 drug-free male schizophrenic patients. 33 of these patients were first studied during chronic haloperidol maintenance treatment. Withdrawal from haloperidol maintenance treatment was associated with a significant increase in CSF CgA-LI, particularly in the patients who did not relapse. Contrary to expectation CSF CgA-LI was higher in drug-free patients who slept longer the night before the lumbar puncture. Significant relationships were observed between CSF CgA-LI and CSF homovanillic acid, acetylcholinesterase, neuropeptide Y-LI and 5-hydrox -indole acetic acid, but not with CSF norepinephrine or 3-methoxy-4-hydroxypphenylglycol. Venticualr brain ratios correlated negatively with CSF CgA-LI levels.